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Bone is the third most common site of
metastasis in cancer patients and a major
source of mortality and morbidity
(Roodman, 2004). The bone is a highly
organized matrix that is uniquely resistant
to degradation but is the subject of con-
stant remodeling, orchestrated by two
highly specialized cells, bone-forming
osteoblasts and bone-degrading osteo-
clasts. Through their capability to tightly
bind to the bone matrix via the integrin
αvβ3, osteoclasts create an extracellular
phagolysosomal compartment in which
the bone matrix becomes demineralized.
The release into this acidic compartment
of cysteine proteinases like cathepsin K
and matrix metalloproteinases (MMPs)
allows the degradation of collagen (Everts
et al., 1992) (Blavier and Delaisse, 1995).
The activity of osteoclasts is under tight
control by osteoblasts. Upon hormonal
stimulation by parathyroid hormone,
osteoblasts become activated and
express at their cell surface the receptor
activator of NFκB ligand (RANKL), a 45
kDa glycosylated (38 kDa unglycosylat-
ed) protein with a transmembrane domain
(Takayanagi et al., 2002). Close contact
between osteoblasts and osteoclast pre-
cursor cells promotes RANKL binding to
its receptor RANK and osteoclast differ-
entiation and activation. RANKL activation
of RANK is further regulated by osteopro-
tegerin (OPG), a soluble RANKL decoy
receptor that interferes with RANK-
RANKL interaction. Tumor cells do not
have the capability to resorb bone, but
through the expression of the osteoblast
activator parathyroid hormone related
peptide (PTHrP) and RANKL can activate
osteoclasts (Mundy, 2002) (Figure 1).
In this issue, the article by Lynch et
al. (2005) illustrates how the careful
study of changes that occur in the bone
microenvironment can lead to findings of
importance in our search for novel tar-
gets for therapeutic intervention in can-
cer. These investigators have developed
a new in vivo model in which prostatic
carcinoma cells obtained in rats treated
with the carcinogen DMAB (3-2′ dimethyl
4-aminobiphenyl) and testosterone pro-
pionate are transplanted into the cranial
region of syngeneic rats or immunodefi-
cient (RAG-2 deficient) mice. After 2 to 4
weeks, they observed radiological and
histopathological changes in the calvaria
that closely reproduce osteolytic and
osteoblastic alterations seen in human
prostate cancer bone metastasis. Using
a combination of RT-PCR and microarray
gene expression analysis on material
specifically collected at the tumor-bone
interface, they documented, not surpris-
ingly, elevated levels of PTHrP, RANKL,
and cathepsin K, and decreased levels
of OPG over time (although OPG levels
were elevated at the beginning).
Interestingly, they also observed elevat-
ed levels of MMP-7, a member of the
MMP family of proteases that has been
previously reported to be overexpressed
in epithelial cancers, including breast
and prostate. This was an unexpected
observation. Many MMPs (9, 10, 12, and
14) have been shown to be expressed by
osteoclasts, but not MMP-7 (Delaisse et
al., 2003). Furthermore, the finding that
MMP-7 was expressed by osteoclasts
and not by prostate cancer cells was at
odds with previous observations demon-
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In this issue of Cancer Cell, a paper by Lynch et al. demonstrates how the careful study of changes that occur at the inter-
face between tumor cells and stromal cells led to the discovery of a new function for matrix metalloproteinase-7 (MMP-7) in
the formation of osteolytic lesions in prostate cancer.The data suggest that MMP-7 inhibition could be a therapeutic target
in prostate cancer.
Figure 1. MMP-7 and osteoclast activation in
cancer
Membrane-associated RANKL expression by
tumor cells or by PTHrP stimulated osteoblasts
promotes the maturation and activation of
osteoclast precursor cells through close cell-
cell contact. Cleavage and solubilization of
RANKL by MMP-7 allows the stimulation of
osteoclasts without the need for cell-cell
contact.
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strating that MMP-7 in tumors is primarily
expressed by malignant cells. A clue,
however, came from a previous observa-
tion made by the laboratory of Dr.
Matrisian, who contributed to the paper.
Her laboratory had demonstrated that
MMP-7 can cleave substrates other than
extracellular matrix (ECM) proteins, and
in particular TNF-α, mediating therefore
cell-cell communication rather than
matrix degradation (Haro et al., 2000).
Aware that RANKL is a member of the
TNF-α family of ligands, the authors pos-
tulated and then elegantly demonstrated
that MMP-7 cleaves RANKL at residues
145–146 in the stalk region of the pro-
tein, releasing an active soluble form of
RANKL from the cell surface. The solubi-
lization of RANKL is not without signifi-
cant consequence, because it eliminates
the need for close contact between
RANKL-expressing cells like osteoblasts
and tumor cells and RANK-expressing
osteoclast precursor cells. That MMP-7
is essential for bone resorption in their
model was then confirmed in immunode-
ficient mice in which MMP-7 had been
knocked down.
The paper illustrates several impor-
tant aspects in our efforts to identify new
targets for therapeutic strategies. In
searching for such targets, it is important
to consider the stromal components of a
tumor (the microenvironment). Well
aware of this, the investigators purposely
performed their gene expression analy-
sis on material obtained at the tumor-
bone interface. However, because they
used a syngeneic model, it was not pos-
sible by gene array analysis only to iden-
tify the source of expression of the genes
they found to be up- or downregulated.
They had to perform a careful immuno-
histological analysis to discover that, in
an unanticipated manner, MMP-7 was
expressed not by prostate cancer cells,
but rather by osteoclasts. Human xeno-
transplanted models in mice, used by
many laboratories, have a significant
advantage in this aspect, because they
allow differentiation of the source of the
genes expressed on the basis of the
species (human versus murine). The
development of gene arrays in which
human and murine sequences are com-
pared, such as that recently developed
by the Protease Consortium (Hu/Mu
ProtIn, Affymetrix), will allow us to
address the critical question of the con-
tribution of the host microenvironment in
these models. A second point that the
paper illustrates is that dogma, although
helpful, should always be revisited. In the
1980s and early 1990s, the consensus
was that the proteolytic activity of MMPs
was primarily directed toward ECM pro-
teins (as reflected by their designation as
matrix proteases). In the late 1990s and
early 2000s, it became apparent that
MMPs can proteolytically process a
large number of growth factors, growth
factor receptors, and cytokines, and
affect their solubilization and biological
activity (McCawley and Matrisian, 2001).
Another dogma is that in contrast to most
MMPs, which are expressed by tumor
cells and stromal cells, MMP-7 was con-
sidered to be primarily expressed by
tumor cells. The authors demonstrate
that this is clearly not always the case.
An important last lesson that this paper
illustrates is that biomedical research,
although moving from the laboratory to
the bedside, needs also to be able to
return from the bedside to the laboratory.
On the basis of promising preclinical
studies, most of them performed in
experimental metastatic models, syn-
thetic MMP inhibitors were tested in clin-
ical trials many years ago. However, the
results of these clinical trials were disap-
pointing, and in some cases indicated
accelerated progression (Coussens et
al., 2002). As a result, most trials with
MMP inhibitors have been abandoned,
and the use of MMP inhibitors as anti-
cancer agents has been considered a
failure. Lynch et al. now suggest that
there could be a very specific window in
cancer progression where the use of a
specific MMP-7 inhibitor in addition to
other therapies could inhibit bone inva-
sion by prostate cancer cells. Patients
with prostate cancer and bone metas-
tases were not included in previous clini-
cal trials. It is not unusual to see
therapeutic agents developed in the past
and abandoned because of a lack of
apparent effect in clinical trials returning
later to the clinic after a better under-
standing of their biological activity. To
convince the pharmaceutical industry to
continue to make MMP inhibitors avail-
able for laboratory research will be criti-
cal in our effort to revisit the use of such
agents in cancer therapy.
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